Table 3.
Heart rate (bpm)
| Test | Placebo (n = 10) | Creatine (n = 10) | ||||
|---|---|---|---|---|---|---|
| HRPEAK | HRER | HRLR | HRPEAK | HRER | HRLR | |
| Trial 1 | ||||||
| T1 | 165 (9) | 105 (11) | 80 (10) | 172 (11) | 115 (15) | 87 (13) |
| T2 | 164 (7) | 104 (11) | 80 (8) | 172 (8) | 114 (15) | 86 (13) |
| T3 | 165 (7) | 101 (9) | 76 (9) | 172 (6) | 110 (15) | 85 (12) |
| T4 | 165 (6) | 98 (9) a | ― | 174 (7) | 106 (15) a | ― |
| Trial 2 | ||||||
| T1 | 163 (8) | 101 (8) | 78 (10) | 171 (9) | 115 (15) | 85 (14) |
| T2 | 164 (5) | 102 (9) | 77 (7) | 172 (9) | 115 (14) | 85 (15) |
| T3 | 162 (5) | 100 (8) | 74 (8) | 171 (8) | 111 (13) | 84 (14) |
| T4 | 165 (6) | 100 (8) | ― | 173 (8) | 112 (12) | ― |
Data are presented as mean (SD). HR PEAK peak heart rate; HR ER early recovery heart rate; HR LR late recovery heart rate; T1–T4—upper-body intermittent sprint performance tests
a Different from T1, P < 0.05